Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis.

Antimicrobial agents and chemotherapy - 1 Mar 1997

Scorpio A, Lindholm-Levy P, Heifets L, Gilman R, Siddiqi S, Cynamon M, Zhang Y

Abstract excerpt

Pyrazinamide (PZA) is a first-line drug for short-course tuberculosis therapy. Resistance to PZA is usually accompanied by loss of pyrazinamidase (PZase) activity in Mycobacterium tuberculosis. PZase converts PZA to bactericidal pyrazinoic acid, and the loss of PZase activity is associated with P...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amidohydrolases
Share to Antitubercular Agents
Share to Drug Resistance, Microbial

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, Bacterial

Share to Mutation

Share to Mycobacterium tuberculosis

Share to Polymorphism, Single-Stranded Conformational

Share to Tuberculosis, Pulmonary

Source

Open in PubMed Open full text

Identifiers

PMID: 9055989
DOI: 10.1128/AAC.41.3.540
PMCID: PMC163747

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026. Prepared record publication-9055989-2026-09-01.1. Manifest publication-graph-cohort-2026-09-01.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis.PMID 9055989Read ↗

Mutation in pncA is a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis.Semantic proximity Read ↗

Molecular characterization of pncA gene mutations in Mycobacterium tuberculosis clinical isolates from China.Semantic proximity Read ↗

Characterization of pncA Mutations and Prediction of PZA Resistance in Mycobacterium tuberculosis Clinical Isolates From Chongqing, ChinaSemantic proximity Read ↗

Characterization of pncA mutations of pyrazinamide-resistant Mycobacterium tuberculosis in Korea.Semantic proximity Read ↗

pncA mutations as a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis: spread of a monoresistant strain in Quebec, Canada.Semantic proximity Read ↗

Genetic and phenotypic characterization of pyrazinamide-resistant mycobacterium tuberculosis complex isolates in Japan.Semantic proximity Read ↗

Patterns of pncA mutations in drug-resistant Mycobacterium tuberculosis isolated from patients in South Korea.Semantic proximity Read ↗

Pyrazinamide Resistance and pncA Mutation Profiles in Multidrug Resistant Mycobacterium TuberculosisSemantic proximity Read ↗

Mycobacterium tuberculosis pyrazinamide resistance determinants: a multicenter study.Semantic proximity Read ↗

Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis in Brazil.Semantic proximity Read ↗

pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis clinical isolates from the southeast region of BrazilSemantic proximity Read ↗

Systematic review of mutations in pyrazinamidase associated with pyrazinamide resistance in Mycobacterium tuberculosis clinical isolates.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.